 |
New Press Release |  | Orqis Medical Completes First in Man Implant of Revolutionary Exeleras Product
New Heart Failure Treatment Improves Cardiac Function without Ever Touching the Heart  |
The MOMENTUM Clinical Trial |  | A clinical trial was conducted to see if patients hospitalized with decompensated heart failure and are inadequately... |
Products |  | Currently the company has two products in development that are being evaluated... |
|
 |
Products
 Orqis develops and sells novel products to improve cardiac performance through aortic flow therapy. The percutaneous Cancion® System is commercially available in select markets. The implantable Exeleras® System is currently in development.
Both products employ Orqis Medical’s proprietary continuous aortic flow augmentation (CAFA) technology.
 |
 |
Sitemap